HC Wainwright Cuts LENZ Therapeutics (NASDAQ:LENZ) Price Target to $48.00

LENZ Therapeutics (NASDAQ:LENZ) had its target price reduced by HC Wainwright from $56.00 to $48.00 in a research note released on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for LENZ Therapeutics’ Q1 2026 earnings at ($1.11) EPS, Q2 2026 earnings at ($1.06) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.83) EPS, FY2026 earnings at ($3.89) EPS, FY2027 earnings at ($2.72) EPS, FY2028 earnings at ($0.88) EPS, FY2029 earnings at $0.61 EPS and FY2030 earnings at $2.38 EPS.

Several other research firms also recently commented on LENZ. Bank of America decreased their price objective on LENZ Therapeutics from $35.00 to $29.00 and set a “buy” rating on the stock in a report on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of LENZ Therapeutics in a report on Thursday, January 22nd. Wall Street Zen downgraded LENZ Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. William Blair reiterated an “outperform” rating on shares of LENZ Therapeutics in a report on Tuesday, March 10th. Finally, Citigroup decreased their price objective on LENZ Therapeutics from $52.00 to $26.00 and set a “buy” rating on the stock in a report on Thursday, March 26th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, LENZ Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

LENZ Therapeutics Stock Down 8.4%

Shares of LENZ stock opened at $9.15 on Tuesday. The business has a 50-day moving average price of $10.99 and a two-hundred day moving average price of $19.69. LENZ Therapeutics has a 12-month low of $8.25 and a 12-month high of $50.40. The firm has a market cap of $286.85 million, a P/E ratio of -3.26 and a beta of 0.66.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings results on Tuesday, March 24th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.25). The business had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $3.09 million. As a group, research analysts expect that LENZ Therapeutics will post -3.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of LENZ. Quarry LP purchased a new position in LENZ Therapeutics during the 3rd quarter valued at about $27,000. Bfsg LLC purchased a new position in LENZ Therapeutics during the 3rd quarter valued at about $30,000. Osaic Holdings Inc. increased its holdings in LENZ Therapeutics by 2,146.2% during the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after purchasing an additional 1,116 shares during the period. Tower Research Capital LLC TRC increased its holdings in LENZ Therapeutics by 51.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after purchasing an additional 477 shares during the period. Finally, SBI Securities Co. Ltd. increased its holdings in LENZ Therapeutics by 9,235.3% during the 3rd quarter. SBI Securities Co. Ltd. now owns 1,587 shares of the company’s stock valued at $74,000 after purchasing an additional 1,570 shares during the period. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics News Roundup

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: HC Wainwright continues to carry a “Buy” rating and a $48.00 price target on LENZ, signaling analyst conviction that there remains significant upside relative to the current share price despite the estimate reductions. HC Wainwright Lowers LENZ Therapeutics (NASDAQ:LENZ) Price Target to $48.00
• Neutral Sentiment: LENZ was included in a broader healthcare analyst roundup (coverage mention only); this keeps the company on analysts’ radar but did not provide new company?specific catalysts. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright materially lowered Q1–Q4 2026 EPS forecasts (Q1 now ($1.11), Q2 ($1.06), Q3 ($0.90), Q4 ($0.83)) and cut FY2026 to ($3.89). These nearer?term downgrades indicate weaker revenue/earnings visibility for 2026 and are a primary driver of downward pressure on the stock.
• Negative Sentiment: Longer?term estimates were also trimmed: FY2027 moved to ($2.72), FY2028 to ($0.88), FY2029 to $0.61 and FY2030 to $2.38 (all revised lower), which delays expected profitability and reduces long?term upside assumptions embedded in prior models.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.